Page 189 - 2019_05-HaematologicaMondo-web

Efficacy of MM treatments
tiple myeloma. Blood. 2016;127(9):1109-
1116.
14. Tierney JF, Stewart LA, Ghersi D, Burdett S,
Sydes MR. Practical methods for incorpo- rating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
15. Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
16. Rucker G, Schwarzer G. Ranking treat- ments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
17. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1 (2):97-111.
18. Rucker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312-324.
19. Rucker G, Schwarzer G. Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in net- work meta-analysis. Stat Med. 2014;33(25): 4353-4369.
20. Bhatnagar N, Lakshmi PV, Jeyashree K. Multiple treatment and indirect treatment comparisons: An overview of network meta-analysis. Perspect Clin Res. 2014;5(4):154-158.
21. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and incon- sistency in network meta-analysis: Concepts and models for multi-arm stud- ies. Res Synth Methods. 2012;3(2):98-110.
22. Krahn U, Binder H, Konig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta- analyses. BMJ. 2003;327(7414):557-560.
24. Higgins JP, Green S, eds. Cochrane hand- book for systematic reviews of interven- tions version 5.1.0. [updated March 2011] ed. The Cochrane Collaboration; 2011. Available from www.handbook.cochrane.org. Available from www.handbook.cochrane.org.
25. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. combina- tion chemotherapy with different melpha- lan dose regimens. JAMA. 1969; 208(9):1680-1685.
26. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A ran- domised trial. Lancet. 2007; 370(9594): 1209-1218.
27. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalido- mide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664- 3670.
28. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with
bortezomib-melphalan-prednisone for ini- tial treatment of multiple myeloma: Updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634-640.
29. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC myeloma IX trial: Survival outcomes with bisphospho- nate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030-6038.
30. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subse- quent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
31. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010; 28(33):4976-4984.
32. Larocca A, Offidani M, Musto P, et al. 744 impact of bortezomib- or lenalidomide- based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the gimema-MM-03-05 and EMN01 trials. Blood. 2017;130(Suppl 1):744.
33. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high- risk cytogenetics: A consensus of the inter- national myeloma working group. Blood. 2016;127(24):2955-2962.
34. Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma- related complications. Haematologica. 2015;100(10):1254-1266.
35. Mateos MV, Oriol A, Martinez-Lopez J, et al. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: Matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016;95(12):2033-2041.
36. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalido- mide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood. 2008;112(8):3107- 3114.
37. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus pred- nisone in elderly patients with newly diag- nosed multiple myeloma: The HOVON 49 study. J Clin Oncol. 2010;28(19):3160-3166.
38. Sacchi S, Marcheselli R, Lazzaro A, et al. A randomized trial with melphalan and pred- nisone versus melphalan and prednisone plus thalidomide in newly diagnosed mul- tiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma. 2011;52(10):1942-1948.
39. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melpha- lan/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the turk- ish myeloma study group. Eur J Haematol. 2011;86(1):16-22.
40. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalido- mide or placebo in elderly patients with multiple myeloma. Blood. 2010; 116(9): 1405-1412.
41. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005; 2(8):e124.
42. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and pred- nisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreat- ed multiple myeloma: A randomised trial. Lancet Oncol. 2010;11(10):934-941.
43. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated eld- erly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-1247.
44. Efthimiou O, Mavridis D, Debray TP, et al. Combining randomized and non-random- ized evidence in network meta-analysis. Stat Med. 2017;36(8):1210-1226.
45. Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: Results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018; 18(10):e401-e419.
46. Schmitz S, Maguire A, Morris J, et al. The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: A network meta-analy- sis in multiple myeloma. BMC Med Res Methodol. 2018;18(1):66.
47. Verelst SGR, Blommestein HM, de Groot S, et al. Long-term outcomes in patients with multiple myeloma: A retrospective analysis of the dutch population-based HAematological regustry for observational studies (PHAROS). HemaSphere. 2018; 2(4):1.
48. Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ. Bortezomib-containing regi- mens (BCR) for the treatment of non-trans- plant eligible multiple myeloma. Ann Hematol. 2017;96(3):431-439.
49. Arditi C, Burnand B, Peytremann- Bridevaux I. Adding non-randomised stud- ies to a cochrane review brings comple- mentary information for healthcare stake- holders: An augmented systematic review and meta-analysis. BMC Health Serv Res. 2016; 16(1):598.
50. Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA. A cost-effectiveness analysis of real- world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2015;96(2):198- 208.
51. Zheng Y, Pan F, Sorensen S. Modeling treat- ment sequences in pharmacoeconomic models. Pharmacoeconomics. 2017; 35(1):15-24.
52. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
haematologica | 2019; 104(5)
1035